Contract Pharmacal's Acetaminophen Recall Signals Persistent Quality Control Challenges
Contract Pharmacal Corporation has initiated a Class II voluntary recall of 14,616 bottles of Extra Strength Acetaminophen 500 MG Tablets due to discoloration. This event, prompted by brownish tablets, highlights ongoing quality control vulnerabilities for the Hauppauge, NY-based manufacturer, impacting supply chain stability for distributors like Major Pharmaceuticals and demanding immediate procurement re-evaluation.
FDA Findings: Discoloration Triggers Class II Acetaminophen Recall
Contract Pharmacal Corporation has initiated a voluntary Class II recall for 14,616 bottles of Extra Strength Acetaminophen 500 MG Tablets, distributed by Major Pharmaceuticals. The recall, identified as D-0566-2024 and initiated on May 20, 2024, stems from a critical quality defect: product discoloration, specifically tablets appearing brownish. This issue affects Lot#: 368638, with an expiration date of May 2025. For procurement directors, this means an immediate assessment of inventory from NDC 0904-6730-60 and UPC 309046730606 is necessary to prevent distribution of compromised product. The Class II classification indicates that while the product defect may cause temporary or medically reversible adverse health consequences, the probability of serious adverse health consequences is remote. However, for regulatory affairs heads, any deviation from product specifications, particularly visible changes like discoloration, signals a potential breach in Good Manufacturing Practices (GMP) and can erode consumer trust, necessitating swift action to quarantine affected batches and manage returns efficiently.
Contract Pharmacal Corporation: Manufacturing Profile and Product Scope
Contract Pharmacal Corporation, based in Hauppauge, NY, United States, operates as a manufacturer specializing in pharmaceutical formulation. While the current recall pertains to Acetaminophen, the company's broader product portfolio includes active pharmaceutical ingredients (APIs) such as Doxepin Hydrochloride, Caffeine, Magnesium Salicylate, and Dimenhydrinate, serving various therapeutic areas including respiratory and dermatology. This diverse manufacturing scope means that quality control issues in one product line, particularly a high-volume OTC drug like Acetaminophen, could indicate systemic vulnerabilities across their operations. For supply chain VPs, understanding this broader context is crucial. A single product recall from a key manufacturer necessitates a review of all products sourced from that facility, even those currently deemed low-risk, as underlying manufacturing or quality system deficiencies could impact other molecules. The company's overall 'low' risk band, as per intelligence, will be re-evaluated in light of this recurring product quality challenge.
Supply Chain Exposure: Impact on Acetaminophen Distribution in Michigan
The voluntary recall of Extra Strength Acetaminophen 500 MG Tablets directly impacts the downstream supply chain, particularly Major Pharmaceuticals, the identified distributor located at 17177 N Laurel Park Drive, Suite 233, Livonia, MI USA 48152. The distribution pattern for the affected lot (Lot#: 368638) was primarily within Michigan (MI). With 14,616 bottles subject to recall, this event represents a significant disruption for regional pharmacies, retailers, and healthcare providers relying on this common OTC pain reliever. Procurement directors must urgently coordinate with Major Pharmaceuticals to identify and isolate all affected stock, manage reverse logistics, and assess the immediate impact on inventory levels. Business development executives should recognize the potential for market gaps created by this disruption, offering opportunities for competitors to gain market share in the Michigan region. Regulatory affairs heads must ensure that all recall communications and procedures adhere strictly to FDA guidelines, minimizing further compliance risks and protecting public health.
Strategic Sourcing: Identifying Alternative Acetaminophen Suppliers
To mitigate the supply chain risks exposed by Contract Pharmacal Corporation's recurring quality issues with Acetaminophen, procurement teams must proactively diversify their supplier base. Several alternative manufacturers and distributors are available in the market. Key alternative suppliers include Allegiant Health, Softgel Healthcare, and Haleon Holdings, all of which represent established entities with capabilities in OTC pharmaceutical production. Other potential options include AvPAK and Chain Drug Marketing Association. Geographically, many of these alternatives maintain a strong presence within the United States, offering stability and reducing reliance on single-point manufacturing. For procurement directors, initiating or accelerating the qualification process for these alternative sources is paramount. This involves rigorous auditing of their quality management systems, manufacturing capabilities, and regulatory compliance history to ensure a robust and resilient supply of critical molecules like Acetaminophen, thereby safeguarding continuity of supply and reducing future disruption exposure.
Contract Pharmacal's Regulatory History: A Pattern of Quality Concerns
This current Class II recall for Acetaminophen discoloration is not an isolated incident for Contract Pharmacal Corporation. The company has a documented history of quality control challenges, notably a prior FDA Class II recall for Acetaminophen due to commingling, which occurred on February 19, 2020. This pattern of recurring issues with the same molecule—Acetaminophen—suggests persistent systemic deficiencies in their manufacturing processes or quality management systems. For regulatory affairs heads, this history elevates the risk profile associated with Contract Pharmacal, indicating a need for intensified scrutiny of their corrective and preventive actions (CAPAs). Procurement directors must factor this repeated non-compliance into their supplier risk assessments, demanding comprehensive root cause analyses and verifiable evidence of sustainable improvements. A continued pattern of quality failures could lead to more severe FDA enforcement actions, including potential import alerts or broader facility restrictions, impacting all products sourced from their Hauppauge, NY site.
Remediation Timeline and Future Regulatory Scrutiny
The Class II recall initiated by Contract Pharmacal Corporation is currently ongoing, requiring the firm to implement and verify the effectiveness of its corrective actions. While specific FDA timelines for remediation are not provided in the immediate recall notice, the agency will closely monitor Contract Pharmacal's response, including the thoroughness of their root cause analysis and the implementation of robust corrective and preventive actions (CAPAs). For regulatory affairs heads, this means ensuring that Contract Pharmacal provides a comprehensive plan to address the discoloration issue, extending beyond the immediate lot to prevent recurrence across all Acetaminophen production. Failure to adequately address these underlying quality system deficiencies could lead to further FDA enforcement, such as additional inspections, official warning letters, or even product seizures. Supply chain VPs should prepare for potential long-term impacts on product availability from this manufacturer and consider strategic shifts in their sourcing strategies to mitigate future supply disruptions.